- Novartis reports that it has reached a “definitive agreement” to buy the Fort Worth, Texas-based Encore Vision, who are developing EV06, a lens softening presbyopia treatment. Financial details of the transaction have not been disclosed.
- Heidelberg Engineering has finally launched its Spectralis OCT angiography module. Currently available in ex-US markets, the unit is designed to be used with new and existing Spectralis devices.
- The 21st Century Cures Act has been passed by the US Congress, after almost three years of waiting. The landmark legislation is intended to fast-track the introduction of new therapies by boosting federal funding and accelerating FDA approval processes.
- The European Commission has granted Novartis approval for the use of ranibizumab in choroidal neovascularization stemming from causes other than neovascular age-related macular degeneration, and choroidal neovascularization secondary to pathologic myopia.
- Bayer and Versant Ventures have announced the launch of BlueRock Therapeutics, a company focused on stem cell therapies, and have committed US$225 million in funding.
- Private investment company Ardian has acquired a majority stake in SCHWIND eye-tech-solutions. Rolf Schwind will continue as CEO and retains a significant interest in the company.
I have an extensive academic background in the life sciences, having studied forensic biology and human medical genetics in my time at Strathclyde and Glasgow Universities. My research, data presentation and bioinformatics skills plus my ‘wet lab’ experience have been a superb grounding for my role as a deputy editor at Texere Publishing. The job allows me to utilize my hard-learned academic skills and experience in my current position within an exciting and contemporary publishing company.
